Cargando…

Dynamics of SARS-CoV-2 exposure in Malawian infants between February 2020 and May 2021

BACKGROUND: Very limited information is available on SARS-CoV-2 seroprevalence in infants in sub-Saharan countries. OBJECTIVE: In this study, we aimed to determine the rate and the temporal evolution of SARS CoV-2 seropositivity in breastfed Malawian infants. STUDY DESIGN: Blood samples (n = 250) fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Baroncelli, Silvia, Galluzzo, Clementina Maria, Orlando, Stefano, Mphwere, Robert, Kavalo, Thom, Luhanga, Richard, Amici, Roberta, Floridia, Marco, Andreotti, Mauro, Scarcella, Paola, Marazzi, Maria Cristina, Giuliano, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477783/
https://www.ncbi.nlm.nih.gov/pubmed/36128323
http://dx.doi.org/10.1016/j.jcvp.2022.100110
Descripción
Sumario:BACKGROUND: Very limited information is available on SARS-CoV-2 seroprevalence in infants in sub-Saharan countries. OBJECTIVE: In this study, we aimed to determine the rate and the temporal evolution of SARS CoV-2 seropositivity in breastfed Malawian infants. STUDY DESIGN: Blood samples (n = 250) from 158 infants, born to HIV-negative women and women living with HIV, collected from February 2020 to May 2021, were first tested using an Anti-IgG/A/M SARS CoV 2 ELISA assay against trimeric spike protein, and then, if positive, confirmed using a second ELISA assay detecting IgG against Receptor Binding Domain. RESULTS: The confirmed prevalence of anti-SARS CoV-2 antibodies was 31.0% (95% CI: 23.7%-38.3%) with no significant difference between HIV-exposed and HIV-unexposed infants (29.3% and 37.1% respectively, P = 0.410). The presence of anti-SARS-CoV-2 IgG was not associated with maternal socioeconomic or demographic indices. CONCLUSIONS: Our data underline the wide spread of the SARS-CoV-2 infection in the pediatric population in sub-Saharan Africa. Design of more specific serological tests for African samples and improvements in serosurveillance programs are needed for more rigorous monitoring of the dynamics of SARS-CoV-2 infection in Africa.